Xiaosong Chen

16PUBLICATIONS
29CO-AUTHORS
Cancer diagnosisPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 02, 2026
Diagnostic Performance of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Evaluating Neoadjuvant Therapy Pathological Response in Breast Cancer.

|May 21, 2024
The 21-Gene Recurrence Score Assay Improved Multidisciplinary Treatment Compliance in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: An Analysis of 2,323 Patients.

Liangqiang Li, Jing Yu, Kunwei Shen

|Feb 08, 2024
Anti-HER2 therapy response assessment for guiding treatment (de-)escalation in early HER2-positive breast cancer using a novel deep learning radiomics model.

Yiwei Tong, Zhaoyu Hu, Haoyu Wang

|Oct 29, 2023
Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy.

Renhong Huang, Zheng Wang, Jin Hong

|May 15, 2023
Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis.

Yanting Shih, Shile Chen, Jie Huang

|Dec 16, 2022
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial.

Jiahui Huang, Yiwei Tong, Jin Hong

Pageof 3

Frequent Collaborators

6 joint publications

Kunwei Shen

3 joint publications

Hao Li

3 joint publications

Feng Xue

3 joint publications

Hua Cao